SciSparc Welcomes Professor Nir Peled to Its Advisory Board
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company specializing in therapies for central nervous system disorders, has made notable progress in its mission. Recently, SciSparc announced that MitoCareX Bio Ltd., its collaborative effort with Dr. Alon Silberman, has appointed Professor Nir Peled to its Scientific Advisory Board.
Professor Nir Peled's Expertise
Professor Nir Peled is a distinguished oncologist who currently leads the Oncology Department at Shaare Zedek Medical Center in Jerusalem. He possesses multiple board certifications, including those in internal medicine, pulmonology, and medical oncology. His vast knowledge and experience have established him as a leading expert in thoracic oncology.
Significant Contributions to Oncology
Professor Peled has made substantial contributions to the research and treatment of lung cancer. He has been a board member of the International Association for the Study of Lung Cancer (IASLC) and has held prominent roles, such as Chair of the Global Multidisciplinary Practice Standards Committee. Recently, he completed his term as Chair of the Thoracic Cancer Assembly of the European Thoracic Society.
His research primarily centers around personalized targeted therapy, immunotherapy, cancer evolution, and the development of biomarkers that facilitate early lung cancer detection. With over 250 peer-reviewed publications to his name, he has provided essential guidelines on early diagnosis, biomarker development, and the treatment of advanced disease.
Innovations at MitoCareX
Dr. Alon Silberman, the CEO of MitoCareX, expressed his enthusiasm in welcoming Professor Peled, emphasizing that his expertise will be crucial in advancing the company's groundbreaking technologies for cancer treatment. MitoCareX is dedicated to drug discovery and development aimed at life-threatening conditions, particularly focusing on the mitochondrial SLC25 protein family.
Focusing on Lung Cancer
A recent breakthrough for MitoCareX was the validation of the SLC25 carrier protein's role in Non-Small Cell Lung Cancer (NSCLC). This significant finding was achieved through genetic manipulations and the use of 3D spheroid systems that replicate human tumors.
Utilizing a sophisticated computational platform, including its proprietary MITOLINE™ algorithm, MitoCareX is screening millions of small molecules. This virtual screening initiative has successfully identified numerous potential anti-cancer treatments, thereby expanding the company's pipeline of therapies.
About SciSparc Ltd.
SciSparc Ltd. is powered by a skilled team committed to advancing cannabinoid pharmaceutical technologies. The company is focused on innovative drug development, with programs such as SCI-110 for Tourette Syndrome, SCI-160 for pain management, and SCI-210 aimed at treating agitation in Alzheimer’s disease and status epilepticus.
Looking Ahead
As SciSparc continues to prioritize research and development, it remains proactive in enhancing its portfolio while exploring the therapeutic potential of cannabinoid medications. With a controlling interest in a subsidiary that markets hemp seed oil products on Amazon Marketplace, SciSparc is well-positioned for strategic growth across various health markets.
Frequently Asked Questions
Who is Professor Nir Peled?
Professor Nir Peled is a prominent oncologist who has been appointed to the Scientific Advisory Board of MitoCareX, bringing his extensive expertise in thoracic oncology.
What is MitoCareX?
MitoCareX is a collaborative venture under SciSparc focused on discovering and developing drugs that target mitochondrial SLC25 proteins for cancer therapies.
What role will Professor Peled play at MitoCareX?
He will offer valuable insights and guidance to help advance the company's innovative technologies for cancer treatment.
What are SciSparc's primary drug development focus areas?
SciSparc is currently concentrating on cannabinoid-based treatments for various disorders, including Tourette Syndrome, Alzheimer's disease, pain management, and autism spectrum disorder.
How is MitoCareX advancing cancer therapy?
MitoCareX employs advanced computational drug discovery techniques and validation studies to identify promising small molecules for effective cancer treatment.
